Preferred Label : Izeltabart Tapatansine;
NCIt synonyms : Anti-ADAM9 Antibody Drug Conjugate IMGC936; Anti-ADAM9/DM21 ADC IMGC936; ADAM9-targeting Antibody-drug Conjugate IMGC936; Anti-ADAM9 ADC IMGC936;
NCIt definition : An immunoconjugate consisting of a humanized monoclonal antibody directed against
the tumor-associated antigen (TAA) disintegrin and metalloproteinase domain-containing
protein 9 (ADAM9) that is site-specifically conjugated, via a stable tri-peptide cleavable
linker, to DM21, a cytotoxic maytansinoid microtubule-disrupting payload, with potential
antineoplastic activity. Upon administration of izeltabart tapatansine, the anti-ADAM9
monoclonal antibody moiety targets and binds to ADAM9 on tumor cells. Upon internalization,
the maytansinoid moiety is released, binding to tubulin and disrupting microtubule
assembly/disassembly dynamics, which may result in the inhibition of cell division
and cell growth of tumor cells. ADAM9, belonging to the a disintegrin and metalloproteinase
(ADAM) family of proteases, plays a key role in cytokine and growth factor shedding
and cell migration. It is overexpressed on multiple solid tumors while minimally expressed
on normal tissue. Dysregulation of ADAM9 has been implicated in tumor progression,
migration and metastasis. Its expression is correlated with poor prognosis. The antibody
is engineered to include a YTE mutation to improve pharmacokinetics.;
UNII : LL3U59WXR1;
CAS number : 2642078-62-2;
Molecule name : IMGC-936; IMGC 936;
NCI Metathesaurus CUI : CL1661889;
Origin ID : C179286;
UMLS CUI : C5706706;
Currated CISMeF NLP mapping
- Semantic type(s)
- concept_is_in_subset
- has_target
